Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP949384.RA-Jyo1GN8qn83Df1n_hBnNPiR_mDXoX2nBwCBiuLvfgE130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP949384.RA-Jyo1GN8qn83Df1n_hBnNPiR_mDXoX2nBwCBiuLvfgE130_assertion type Assertion NP949384.RA-Jyo1GN8qn83Df1n_hBnNPiR_mDXoX2nBwCBiuLvfgE130_head.
- NP949384.RA-Jyo1GN8qn83Df1n_hBnNPiR_mDXoX2nBwCBiuLvfgE130_assertion description "[Intervention trials of the synthetic nrf2 activator, bardoloxone methyl, in patients with advanced diabetic nephropathy, showing improvement of renal function and decreased inflammation, suggest that nrf2 activators may have therapeutic benefit in chronic renal failure.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP949384.RA-Jyo1GN8qn83Df1n_hBnNPiR_mDXoX2nBwCBiuLvfgE130_provenance.
- NP949384.RA-Jyo1GN8qn83Df1n_hBnNPiR_mDXoX2nBwCBiuLvfgE130_assertion evidence source_evidence_literature NP949384.RA-Jyo1GN8qn83Df1n_hBnNPiR_mDXoX2nBwCBiuLvfgE130_provenance.
- NP949384.RA-Jyo1GN8qn83Df1n_hBnNPiR_mDXoX2nBwCBiuLvfgE130_assertion SIO_000772 22200442 NP949384.RA-Jyo1GN8qn83Df1n_hBnNPiR_mDXoX2nBwCBiuLvfgE130_provenance.
- NP949384.RA-Jyo1GN8qn83Df1n_hBnNPiR_mDXoX2nBwCBiuLvfgE130_assertion wasDerivedFrom befree-2016 NP949384.RA-Jyo1GN8qn83Df1n_hBnNPiR_mDXoX2nBwCBiuLvfgE130_provenance.
- NP949384.RA-Jyo1GN8qn83Df1n_hBnNPiR_mDXoX2nBwCBiuLvfgE130_assertion wasGeneratedBy ECO_0000203 NP949384.RA-Jyo1GN8qn83Df1n_hBnNPiR_mDXoX2nBwCBiuLvfgE130_provenance.